Advances in Treatment of Previously Treated Ph+ Chronic Myeloid Leukemia

Experts come together to share their perspective on the paradigm of previously treated Ph+ chronic myeloid leukemia.

EP. 1: An Overview of Chronic Myeloid Leukemia (CML)

December 14th 2021

Expert overview of chronic myeloid leukemia, including considerations for the unmet needs in management as they exist today.

EP. 2: Chromosomal Abnormalities and Genetic Alterations in CML

January 19th 2022

Shared insight on chromosomal abnormalities and genetic alterations that influence the disease course and management of CML.

EP. 3: Chronic Myeloid Leukemia: Assessing Treatment Response

January 19th 2022

Key opinion leader perspectives on assessing a patient’s response to therapy for chronic myeloid leukemia.

EP. 4: Role of Tyrosine Kinase Inhibitors in Treatment of CML

January 26th 2022

Daniel DeAngelo, MD, PhD, highlights the role that tyrosine kinase inhibitors play in the CML treatment paradigm.

EP. 5: Selecting Second-Line Therapy for Chronic Myeloid Leukemia

January 26th 2022

Considerations for selecting optimal second-line therapy for chronic myeloid leukemia when a patient progresses.

EP. 6: CML: Challenges and Unmet Needs in Later-Line Therapy

February 2nd 2022

A brief review of the inherent challenges in guiding patients through several lines of therapy for chronic myeloid leukemia.

EP. 7: CML: Third-Line Treatment Options for Chronic Myeloid Leukemia

February 2nd 2022

Jorge Cortes, MD, breaks down third-line treatment options for patients who progress with chronic myeloid leukemia.

EP. 8: CML: Asciminib Use in Later-Line Chronic Myeloid Leukemia

February 9th 2022

Shared insight on asciminib’s role in chronic myeloid leukemia in light of available clinical data.

EP. 9: CML Management: Personal Experience With Asciminib

February 9th 2022

Experts share their personal experience with asciminib as later-line therapy for patients with chronic myeloid leukemia.

EP. 10: Chronic Myeloid Leukemia: Asciminib’s Toxicity Profile

February 16th 2022

A brief review of asciminib’s toxicity profile and how to best manage adverse events in patients with chronic myeloid leukemia.

NEXT PAGE
PREVIOUS PAGE